Gaslightwala Abizer reported grant involving 6,430 shares of Akari Therapeutics Plc at $9.72 for $62.5k on Sep 29, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
CEO
CEO
Filed Oct 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$62,499.60Shares × reported price
Shares traded
6,430American Depositary Shares representing Ordinary Shares
Price per share
$9.72Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
14,107Direct
Trade date
Sep 29, 2026Grant
Filed
Oct 1, 2026, 4:50 PM ET2-day reporting delay
Accession
0001493152-26-045366Code A · Transaction 233057
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

AKTX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
AKTX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +21%1w ago +14%1d ago +11%
Returns since7d −8%30d −6.8%90d180d1y

Footnotes in full

F1: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. RSUs were granted on September 29, 2026 and vest in four approximately equal quarterly installments on November 18, 2026, February 18, 2027, May 18, 2027, and August 18, 2027, subject to continued service. The RSUs are subject to forfeiture and cancellation if the Issuer's shareholders do not approve an amendment to the Issuer's equity incentive plan increasing the number of shares reserved for issuance under the plan.